The aim of this study was to investigate the effect of a bone marrow transplantation (BMT) on renal function in children. In a 5-year period, 142 children received a BMT at the Department of Pediatrics of the University Hospital Leiden. The study was performed retrospectively using the estimated glomerular filtration rate before and 1 year after BMT, and weekly measurements of serum creatinine during the first 3 months after BMT for assessment of renal function. Patient characteristics (sex, age, diagnosis), conditioning regimen, type of BMT, major complications (sepsis, veno-occlusive disease and graft-versus-host disease (GVHD)) and the use of nephrotoxic medication were listed. In the first 3 months after BMT 17 (12%) patients died, 13 from transplant-related complications other than renal failure and four from relapse of the disease. Forty-eight children (34%) had a period with acute renal insufficiency. A high pre-BMT serum creatinine, transplantation with either a non-HLA-identical related or a matched unrelated donor were risk factors for acute renal insufficiency after BMT. Sepsis and the use of intravenous vancomycin were risk factors for acute renal insufficiency only for patients with a high pre-BMT serum creatinine. GVHD seemed to have a beneficial effect on renal function of BMT recipients. One year after BMT a total of 35 (25%) patients had died, 16 from transplant-related complications and 19 from relapse of the disease; another 17 patients could not be evaluated. Twenty-five of 90 evaluable children (28%) had chronic renal insufficiency. Chronic renal insufficiency 1 year after BMT was correlated with a high serum creatinine in the first 3 months after BMT. None of the children of this retrospective study on renal function after BMT needed dialysis. Keywords: bone marrow transplantation; child; renal insufficiency BMT has proven to be a good therapeutic approach for a wide range of hematologic, neoplastic, immunologic and Correspondence: Dr JE Kist-van Holthe, Department of Pediatrics, University Hospital Leiden, Postbus 9600, 2300 RC Leiden, The Netherlands Received 12 January 1998; accepted 7 May 1998 metabolic diseases. In the first 3 months post-BMT the transplant-related mortality rate approximates 10-20% in children.
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1,2 The 5-year survival rate, dependent on the disease for which the bone marrow transplantation has been performed, varies from 90% for immunodeficiencies to 25% for hematologic malignancies in third remission. 1 The main steps of BMT are conditioning with intensive chemoradiotherapy to obtain engraftment of donor stem cells in the recipient, and prolonged immunosuppression to prevent GVHD. Major complications are (opportunistic) infections, GVHD and recurrence of primary disease. A major posttransplant complication that may contribute to transplantrelated mortality is acute renal insufficiency. 3, 4 As BMT is the only curative therapy for some diseases, assessment of late complications becomes increasingly important. Understanding of the possible risk factors and the pathogenesis of acute and chronic renal insufficiency after BMT are required in order to reduce its incidence. Data on the incidence and etiology of acute and chronic renal insufficiency in children after BMT are scarce. We studied all children who received a BMT in a 5-year period at our institution.
Patients and methods
From January 1990 to January 1996, 142 children received an allogeneic BMT at the Department of Pediatrics of the University Hospital Leiden. The patients were studied retrospectively from medical records. Characteristics of the patients are given in Table 1 . Type of BMT, conditioning regimen, major clinical problems (sepsis, veno-occlusive disease, GVHD) and the use of nephrotoxic medication (cyclosporin A, aminoglycosides, teicoplanine, vancomycin, amphotericin B) were recorded. During the first 3 months, the patients received cyclosporin A intravenously (2 mg/kg/day). After 2-3 months, cyclosporin A was given orally (6 mg/kg/day). Surveillance of possible cyclosporin A toxicity was performed once a week on a trough level not exceeding 300 g/l blood. The estimated glomerular filtration rate (GFR) was used to study renal function before and 1 year after BMT using a modified Schwartz formula (40 × length (cm)/serum creatinine (mol/l). 5 Chronic renal insufficiency was defined as an estimated GFR Ͻ85 ml/min/1.73 m 2 1 year after BMT. Weekly measurements of serum creatinine were used to study renal function of the patients in the first 3 months after BMT. Acute renal insufficiency was defined as at least doubling of pre-BMT serum creatinine concentration in the first 3 months after BMT. Serum creatinine concentration was measured using a photometric method on an automatic analyzer (Hitachi 747-100; Roche, Almere, The Netherlands).
Statistics
A repeated measurements analysis of variance approach (using BMDP 5V to allow for missing values) was used to study changes in the serum creatinine concentration as a function of time since BMT. Covariates were either timeindependent (eg pre-BMT creatinine level, gender, age at transplant, diagnosis, medication, conditioning regimen) or time-dependent (sepsis, medication, renal failure). Each risk factor (covariate) was analyzed in turn for its possible association with the level itself, as well as the change in serum creatinine during the weeks after BMT.
For statistical significance testing the likelihood ratio test was used at the 5% level; 95% (approximate) confidence intervals were computed to assess the impact of each factor, based on the Wald test. Although each risk factor (covariate) is assessed in turn (so 'univariately'), each analysis is a multivariate one, always correcting the effect (impact) of the risk factor under study for age at transplant and pre-BMT serum creatinine concentration. Effect estimates and 95% confidence intervals are shown as (estimate)(lower bound, upper bound).
Results
None of the 142 children who received a BMT in the 5-year study period was excluded from the study. The type of BMT, conditioning regimen and doses, major clinical complications (sepsis, GVHD, veno-occlusive disease), use of nephrotoxic medication, death and renal insufficiency data are depicted in Table 2 . Of 91 children who received radiation, 82 children had total body irradiation (TBI), while in nine radiation was restricted to the thoracoabdominal region. Seventeen patients (12%) died within 3 months after BMT. The causes of death р3 months were infection (11), relapse of primary disease (four), cardiac arrest (one) and multi-organ failure (one). The mean estimated GFR of the patients before BMT was 124 (s.d. 27) 561 Table 3 Effects of time-independent risk factors on the serum creatinine levels during the first 3 months after BMT (as a function of time, if significantly depending on 'week-since-BMT') The mean post-BMT creatinine level is evaluated for an average child at 7 weeks post BMT, of age 6 years with a pre-BMT creatinine level of 38 mol/l. The effect of each risk factor is tabulated in column Effect (week = 5). If the effect of a risk factor depends on the actual week (significant factor × time interaction), the column 'effect' actually contains the effect at 5 weeks post-BMT while the impact of 4 additional weeks post BMT on magnitude is visualized in the column 'Effect modification: effect (week = 9)'. The column, P value' lists the P value of the main effect of the risk factor in the absence of interaction; it lists the P value of the factor × time effect in the case of effect modification by time.
The column with the '95% confidence interval' states the lower and upper bound relative to the effect in the prior column (the numbers being ±1.96 × s.e. (effect)).
Factors with a P value Ͻ5% are shown in bold.
ml/min/1.73 m 2 . Only one patient (above the age of 1 year) had an estimated GFR Ͻ85 ml/min/1.73 m 2 before BMT. The normal range for GFR under the age of 1 year is 40-100 ml/min/1.73 m 2 . Forty-eight (34%) patients had a period with acute renal insufficiency during the first 3 months after BMT. Of these children, eight (17%) died within 3 months after BMT, but not as a direct consequence of renal insufficiency. The median time which elapsed between BMT and acute renal insufficiency was 6 weeks (min 2 weeks, max 13 weeks). A high pre-BMT serum creatinine concentration and transplantation with a non-HLA-identical related or a matched unrelated donor compared to a HLA-identical sibling were independent risk factors for acute renal insufficiency during the first 3 months after BMT. Sepsis and the use of intravenous vancomycin were risk factors for acute renal insufficiency only for patients with a high pre-BMT serum creatinine. On the contrary GVHD had a positive effect on renal function (Tables 2, 3 and 4) .
One year after BMT, 35 (25%) patients had died, from relapse of the primary disease (19) and from transplantrelated complications (16). These patients could therefore not be evaluated. Estimated GFR 1 year after BMT could not be retrieved in 17 (16%) of the surviving 107 patients. Most of these children were living abroad. Twenty-five patients (28%) had chronic renal insufficiency, defined as an estimated GFR Ͻ85 ml/min/1.73 m 2 1 year after BMT. The median estimated GFR of the 90 evaluable patients 1 year after BMT had significantly (P Ͻ 0.001) decreased from 121 (range 67-209) to 82 (range 24-154) ml/min/1.73 m 2 , (Table 2) . A high serum creatinine in the first 3 months after BMT was shown to be a risk factor for the development of chronic renal insufficiency 1 year after BMT (P Ͻ 0.05). We found no significant correlation between the estimated GFR 1 year after BMT and the radiation dose or the number of fractions used. None of the children of this retrospective evaluation needed dialysis.
Discussion

Acute renal insufficiency
The percentage of children in our study with acute renal insufficiency (34%), is favorable compared to the (scarce) data in the literature on acute renal insufficiency after BMT in children. In a study of 64 children, 50% had renal insufficiency. Renal insufficiency was defined as in our study as at least doubling of pre-BMT serum creatinine concentration within 60 days after BMT. 3 In a study of 649 children, 5% required dialysis for acute renal failure after BMT. 6 None of our patients required dialysis nor died as a consequence of acute renal failure.
In adult BMT recipients, the incidence of acute renal insufficiency is comparable to that in children. In a study of 272 patients, 53% at least doubled their serum creatinine 562 Table 4 Effects of time-dependent risk factors on the serum creatinine levels during the first 3 months after BMT; effect measured in the week after change in risk factor status (as a function of pre-BMT-creatinine level, if significantly depending on the pre-BMT level) The mean post-BMT creatinine level is evaluated for an average child at 7 weeks post-BMT, of age 6 years with a pre-BMT creatinine level of 38 mol/l. The effect of each risk factor is tabulated in column Effect (pre-creatinine = 38). If the effect of a risk factor depends on the actual pre-BMT creatinine level (significant factor × pre-creat interaction), the column 'effect' actually contains the effect at pre-creatinine = 38 while the impact of 10 mol/l increase in pre-creatinine on magnitude is visualized in the column 'Effect modification: effect (pre-creat = 48)'. The column 'P value' lists the P value of the main effect of the risk factor in the absence of interaction; it lists the P value of the factor × time effect in the case of effect modification by time.
The column with the '95% confidence interval' states the lower and upper bound relative to the effect in the prior column (the numbers being ±1.96 × s.e. (effect)). Factors with a P value Ͻ5% are shown in bold.
and 24% required dialysis within 21 days post-BMT. The degree of glomerular impairment had a dramatic impact on patient mortality rates: 84%, 37% and 17%, respectively, for a group of patients requiring dialysis, with mild, and without renal insufficiency. 4 In another study on 183 adult BMT recipients, 36% developed acute renal insufficiency (at least doubling of pre-BMT serum creatinine concentration) while after autologous BMT this was only 6.5%. Twenty-four percent of the patients with acute renal insufficiency required hemodialysis. The overall mortality from acute renal insufficiency was 46%, the dialyzed group having the highest mortality (88%). 7 In a prospective study of 64 adult BMT recipients, 64% of the patients developed acute renal insufficiency, ie at least doubling of pre-BMT serum creatinine concentration. 8 In our study a high pre-BMT serum creatinine, transplantation with a non-HLA-identical related or matched unrelated donor compared to a HLA-identical sibling were risk factors for the development of acute renal insufficiency in the first 3 months after BMT. Sepsis and the use of intravenous vancomycin were risk factors only for patients with a high pre-BMT serum creatinine. Veno-occlusive disease nearly reached significance as a risk factor for acute renal insufficiency (Tables 3 and 4 ). GVHD had no adverse effect on renal function of BMT recipients, but on the contrary seemed to have a beneficial effect on renal function. Possible explanations for this finding may be the use of high-dose corticosteroid medication or lower cyclosporin A blood levels in patients with GVHD of the gut, due to malabsorption. In a study of van Why et al 3 on 64 pediatric patients, the three major predictors of acute renal insufficiency following BMT were conditioning with TBI, cyclosporin A and amphotericin B. As 92% of our patients received cyclosporin A, we could not assess its role in the occurrence of acute renal insufficiency after BMT. Lane et al 6 observed that 30 children requiring dialysis for acute renal insufficiency were different from the general pediatric BMT population for two reasons: there were more children with a neuroblastoma and fewer autologous and more unrelated BMT donors in the dialysis group. Sepsis was the most frequently cited cause in this study, which lead to renal insufficiency and death in 77% of patients. In a study in adults, a pre-BMT serum creatinine concentration у62 mol/l (0.7 mg/dl), sepsis, hypotension, hepatic dysfunction, weight gain and amphotericin B were independently associated with the development of acute renal insufficiency. 4 In another study in adults only, veno-occlusive disease and an age older than 25 years were found to be risk factors related to the development of acute renal insufficiency. 7 Besides the obvious reasons for acute renal insufficiency following BMT such as reduced renal reserve after intensive chemotherapy and the direct effect of nephrotoxic medication, the causes of renal impairment following BMT are thought to be hemodynamic in origin. In support of this assumption are the occurrence of acute renal insufficiency after septicemia (hypotension), veno-occlusive disease (hepato-renal syndrome), amphotericin B administration (renal vasoconstriction) and a high serum urea/creatinine ratio consistent with prerenal insufficiency in adult studies. 4 In our study we did not find an association between renal impairment and hemodynamic effects.
Chronic renal insufficiency
In our patient group, 28% of the children were found to have chronic renal insufficiency 1 year after BMT. The 563 finding that a high serum creatinine in the first 3 months after BMT is a risk factor for developing chronic renal insufficiency 1 year after BMT emphasizes the importance of trying to elucidate and prevent renal insufficiency in the first 3 months after BMT. Berg and Bolme 9 found a significant decrease in glomerular filtration rate (inuline clearance) in 44 children 1 year after BMT compared to their pre-BMT values. These children had primary diseases comparable to those of the children in our study. The mean glomerular filtration rate 1 year after BMT had decreased from 110 to 85 ml/min/1.73 m 2 . After the first year, no further decrease in kidney function occurred. In another pediatric study of 39 patients alive and in remission 6 months after BMT, 16 (41%) children had developed renal insufficiency. 10 The patients had either been treated for neuroblastoma or a relapse of acute lymphoblastic leukemia. The preparation for neuroblastoma patients included teniposide, cis-platinum, melphalan, cyclophosphamide and fractionated TBI, 12 Gy as total dose. In our study group, none of the children were treated for neuroblastoma. Cisplatinum, known for its nephrotoxicity, was not used in our study and a large part (58 of 91) of our patient population received a lower dose TBI, ie 5-8 Gy in one fraction. Renal biopsies of the patients of the study of Tarbell et al 10 were consistent with radiation nephropathy. The clinical symptoms could, however, either be consistent with radiation nephropathy or hemolytic uremic syndrome. Hemolytic uremic syndrome is described and may occur between 3 and 9 months post-BMT. 11, 12 In our patient group hemolytic uremic syndrome did not occur.
In larger series of adult graft recipients, chronic renal insufficiency was found in up to 20% of survivors of BMT. 13 TBI is thought to be a major factor in causing chronic renal insufficiency after BMT. Previous or concurrent chemotherapy may potentiate the effect of radiation on the kidney. The reason for the lower frequency of impaired renal function 1 year after BMT in our patient group compared to other pediatric studies is not clear. In our patient group we found no correlation between serum creatinine 1 year after BMT and radiation pre-BMT. The radiation dose in our patients was slightly lower (58 patients received 5-8 Gy in one fraction, dose rate 25 cGy/min, while 32 patients received 12 Gy in two fractions) than that in other studies: 10 Gy in one fraction, 9,11 12-14 Gy in six to eight fractions 10 and 13 Gy in eight fractions. 3 This might influence the incidence of chronic renal insufficiency after BMT. In animal studies the biological equivalent of radiation is smaller when given in several fractions compared to the same dose given in one fraction.
14 Recently Lawton et al 15 found in a group of 17 adult BMT recipients with renal shielding of 30% (renal radiation dose 9.8 Gy) that none of the patients developed BMT nephropathy, whereas in 72 patients with no renal shielding (TBI 14 Gy) 29% did acquire BMT nephropathy. BMT nephropathy was defined as an increased serum creatinine, anemia and hypertension without any obvious causes other than TBI (ie sepsis, cyclosporin toxicity, anti-fungal therapy, or significant GVHD). The results of this study in adults who received a higher radiation dose compared to children cannot be extrapolated to children. Futher studies in children are required. If radiation is a major factor in causing chronic renal insufficiency after BMT in children, single dose may be replaced by fractionated radiation or renal shielding may be used while still achieving total immune suppression and tumor eradication.
In conclusion, acute renal insufficiency is a frequent complication after BMT. The etiology is multifactorial. In our study it was related to pre-BMT serum creatinine concentration and type of BMT. Sepsis and the use of vancomycin were risk factors for acute renal insufficiency only in patients with a high pre-BMT serum creatinine. The finding that a high serum creatinine in the first 3 months after BMT is a risk factor for the development of chronic renal insufficiency 1 year after BMT emphasizes the importance of attempting to elucidate and prevent renal insufficiency in the first 3 months after BMT. Follow-up of patients with chronic renal failure is needed in order to predict the long-term prognosis. Future prospective studies are required to clarify the causes and prevent acute and chronic renal insufficiency after BMT.
